diagnost tool
diagnost tool
price close busi may
extend lh also open network
includ certainli posit quest
rais pt reiter out-of-consensu buy rate
becom in-network lab provid unitedhealthcar
add access million live begin januari view
materi win quest expect take volum lh plan open
also reiter consensu buy rate lh despit fact expect
revenu attrit relat unit think lh may gain access aet
exclus believ may get updat aet contract live
within next quarter updat either model time
lower pt lh rais pt street-high
would put new money struggl understand
bear case lh gain access aet view risk lh stock
big news unitedhealthcar announc close today
becom in-network nation provid lab servic plan particip
total live begin januari addit announc
renew lab servic relationship labcorp specif term deal
disclos though confirm multi-year deal lab
quest view quest held call close indic expect take
volum lh shift evolutionari flip overnight
price deal suggest strateg relationship hunt licens low-
price deal past price consist base price character
fair exhibit price disciplin negoti plu performance-bas
incent relat servic qualiti contract durat
year rang like guid impact next analyst day late
expect hit higher end revenu rang
labcorp view spoke lh close indic expect
lose volum certainli half volum right away indic
lab revenu loss revenu manag
renew deal multi-year deal hope someth
announc aet fairli soon
view either big winner increment winner depend outcom
aet contract expect aet contract open includ
lh peg increment net winner keep lh aet
relationship take share lh would peg big winner
estim revenu could go lh relat
contract time updat estim lh
time said lh indic lab revenu
know contract year clear us could captur
volum within year call lack
visibl initi think could captur lh
revenu within year year think could captur
revenu rough number would haircut net revenu
gain roughli half contract aet open lh
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
diagnost tool
 pt use multipl
adj ep estim note revenu
ep estim includ expect addit revenu volum gain
relat contract begin januari
laboratori corpor america hold lh pt use
multipl adj ep estim ep
estim includ view lh like lose volum revenu
longer exclus nation lab provid howev believ
lh mitig loss believ lh may abl obtain access aet
present exclus
recent attend lh analyst day host investor meet
takeaway lh analyst day found
takeaway ndr found
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
canaccord genuiti estim compani report
diagnost tool
canaccord genuiti estim compani report
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin may et
date time product may et
pt use multipl adj ep estim note revenu ep estim
includ expect addit revenu volum gain relat contract begin januari
laboratori corpor america hold lh
pt use multipl adj ep estim ep estim includ view lh
like lose volum revenu longer exclus nation lab provid howev believ lh
mitig loss believ lh may abl obtain access aet present exclus
pt use multipl adj ep estim note revenu ep estim
includ expect addit revenu volum gain relat contract begin januari
laboratori corpor america hold lh
pt use multipl adj ep estim ep estim includ view lh
like lose volum revenu longer exclus nation lab provid howev believ lh
mitig loss believ lh may abl obtain access aet present exclus
risk achiev target price valuat
econom downtown would impact busi unemploy rate hover around variou macroeconom
headwind potenti reduc demand diagnost servic especi drugs-of-abus doa pre-employ test
rel cyclic busi segment revenu volum
healthcar reform lead medicar reimburs cut quest deriv approxim net revenu medicar
medicaid program combin medicar clinic lab fee schedul clf medicar physician fee schedul
medicaid lab industri provid face declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost
quest face competit threat could slow growth quest compet primarili labcorp along numer smaller
independ nich clinic laboratori also compet hospit lab quest slightli larger scale scope
labcorp smaller competitor may prove nimbl innov quest labcorp australian-bas sonic healthcar
build signific presenc compet quest acquisit northeast compet bio-refer
lab compani deriv revenu higher-margin esoter test
negoti health plan plan includ manag care organ health insur provid repres
approxim compani volum revenu compani largest health plan aetna repres approxim
compani revenu quest compet aggress labcorp contract health plan larg price margin
contract length quest largest health plan account approxim revenu volum
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
diagnost tool
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
econom downtown would impact busi unemploy rate hover around variou macroeconom
headwind potenti reduc demand diagnost servic especi drugs-of-abus doa pre-employ test
rel cyclic busi segment revenu volum
healthcar reform lead medicar reimburs cut quest deriv approxim net revenu medicar
medicaid program combin medicar clinic lab fee schedul clf medicar physician fee schedul
medicaid lab industri provid face declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost
quest face competit threat could slow growth quest compet primarili labcorp along numer smaller
independ nich clinic laboratori also compet hospit lab quest slightli larger scale scope
labcorp smaller competitor may prove nimbl innov quest labcorp australian-bas sonic healthcar
build signific presenc compet quest acquisit northeast compet bio-refer
lab compani deriv revenu higher-margin esoter test
negoti health plan plan includ manag care organ health insur provid repres
approxim compani volum revenu compani largest health plan aetna repres approxim
compani revenu quest compet aggress labcorp contract health plan larg price margin
contract length quest largest health plan account approxim revenu volum
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
distribut rate
global stock rate
total includ stock review
diagnost tool
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
